Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arcturus Therapeutics Holdings Inc.
< Previous
1
2
Next >
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
September 30, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
ASX:CSL
CSLLY
OTC
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 13, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
ASX:CSL
CSLLY
OTC
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 27, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 05, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
August 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 18, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
July 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
June 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 28, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
May 15, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
May 08, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
April 25, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
March 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
February 26, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
February 22, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
February 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 04, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
November 28, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
ASX:CSL
CSLLY
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
November 27, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
November 14, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
October 25, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
October 23, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
October 04, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
September 26, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
September 19, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
September 05, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
ASX:CSL
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
August 07, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
July 24, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
June 01, 2023
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Tickers
ARCT
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright